LOS ANGELES, July 15, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised ...

HROW sets ambitious price targets in a new 3-year plan while showcasing strong drug growth and leveraging a proven model for ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

Harrow is a strong swing trade in the $20s, with long-term upside as sales and new product launches drive sustained profits.

Our tireless food critics and writers went into the tagliatelle trenches, emerging with a list of Greater Boston’s very best ...

Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William ...

We feel now is a pretty good time to analyse Harrow, Inc.'s (NASDAQ:HROW) business as it appears the company may be on the cusp of a considerable accomplishment. Harrow, Inc., an eyecare ...